Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 9—September 2005

Multidrug-resistant Tuberculosis Detection, Latvia

Girts Skenders*, Alicia M. Fry†, Inga Prokopovica*, Silvija Greckoseja*, Lonija Broka*, Beverly Metchock†, Timothy H. Holtz†, Charles D. Wells†Comments to Author , and Vaira Leimane*
Author affiliations: *State Centre of Tuberculosis and Lung Diseases, Riga, Latvia; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 2

Drug-susceptibility profiles for patients at high risk for MDR-TB with acid-fast bacilli–positive respiratory specimens*†

Drug resistance No. (%)
None 35 (40.0)
Any resistance 52 (60.0)
Rifampin (total) 34 (38.6)
Mono-rifampin 1 (1.1)
MDR (total) 33 (37.5)
R, H 2 (2.3)
R, H, S 17 (19.3)
R, H, S, E 14 (15.9)
Isoniazid (total) 52 (59)
Mono-isoniazid 5 (5.7)
H, S 14 (15.9)

*N = 88; includes 86 Mycobacterium tuberculosis isolates from BACTEC plus 2 isolates that grew on Löwenstein-Jensen media.
†R, rifampin; H, isoniazid; S, streptomycin; E, ethambutol; MDR-TB, multidrug-resistant tuberculosis.

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.